D&D Pharmatech Inc.
Clinical-stage biopharma developing GLP-1 therapies for metabolic and neurodegenerative diseases.
347850 | KO
Overview
Corporate Details
- ISIN(s):
- KR7347850000
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 수정구 금토로80번길 27 (금토동, 텔레칩스) 4층, 성남시
- Website:
- http://www.ddpharmatech.com/
- Sector:
- Manufacturing
Description
D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-10 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.6 KB | ||
| 2024-12-10 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.7 KB | ||
| 2024-11-25 00:00 |
기업설명회(IR)개최
|
Korean | 6.7 KB | ||
| 2024-11-22 00:00 |
투자판단관련주요경영사항 (DD02S 관련 마일스톤 기술료 수령)
|
Korean | 7.2 KB | ||
| 2024-11-14 00:00 |
분기보고서 (2024.09)
|
Korean | 1.1 MB | ||
| 2024-10-15 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.8 KB | ||
| 2024-09-23 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 94.6 KB | ||
| 2024-09-19 00:00 |
본점소재지변경
|
Korean | 5.2 KB | ||
| 2024-08-29 00:00 |
기업설명회(IR)개최
|
Korean | 6.7 KB | ||
| 2024-08-21 00:00 |
기업설명회(IR)개최
|
Korean | 6.7 KB | ||
| 2024-08-14 00:00 |
반기보고서 (2024.06)
|
Korean | 1.4 MB | ||
| 2024-08-08 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 145.9 KB | ||
| 2024-07-11 00:00 |
주식매수선택권부여에관한신고
|
Korean | 22.2 KB | ||
| 2024-07-01 00:00 |
회사합병결정(종속회사의주요경영사항)
|
Korean | 18.8 KB | ||
| 2024-06-10 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정) (대사이상지방간염 (MASH) 치료제 DD01의 제2상 미국 FDA …
|
Korean | 11.7 KB |
Automate Your Workflow. Get a real-time feed of all D&D Pharmatech Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for D&D Pharmatech Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for D&D Pharmatech Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
